Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis

Phase 4

Completed

Conditions: Candidemia
Invasive Candidiasis

Interventions: Drug: Anidulafungin
Drug: Voriconazole

First Posted Date: 2007-10-23

Last Posted Date: 2011-01-17

Lead Sponsor: Pfizer

Target Recruit Count: 54

Registration Number: NCT00548262

Locations: 🇵🇦
Pfizer Investigational Site, Panama, Panama

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Phase 2

Completed

Conditions: Carcinoma, Non Small Cell Lung

Interventions: Drug: PF-00299804

First Posted Date: 2007-10-23

Last Posted Date: 2019-05-21

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT00548093

Locations: 🇺🇸
Grady Health Systems, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 16 locations

Fesoterodine "add-on" Male Overactive Bladder Study

Phase 3

Completed

Conditions: Overactive Bladder Syndrome

Interventions: Drug: Placebo
Drug: Fesoterodine

First Posted Date: 2007-10-19

Last Posted Date: 2011-02-18

Lead Sponsor: Pfizer

Target Recruit Count: 947

Registration Number: NCT00546637

Locations: 🇹🇭
Pfizer Investigational Site, Amphoe Mueang, Chiang Mai, Thailand

First Safety Study in Humans of a Single Dose of CPG 52364

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: 52364 3 mg
Drug: 52364 30 mg
Drug: 52364 1 mg
Drug: 52364 100 mg
Drug: 52364 10 mg

First Posted Date: 2007-10-19

Last Posted Date: 2009-03-19

Lead Sponsor: Pfizer

Target Recruit Count: 61

Registration Number: NCT00547014

Locations: 🇺🇸
Pfizer Investigational Site, Overland Park, Kansas, United States

A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone

Phase 2

Completed

Conditions: Palliative Care
Neoplasm Metastasis

Interventions: Drug: Tanezumab 10 mg IV
Drug: IV Placebo for tanezumab

First Posted Date: 2007-10-17

Last Posted Date: 2021-06-18

Lead Sponsor: Pfizer

Target Recruit Count: 59

Registration Number: NCT00545129

Locations: 🇱🇻
10th Department, Latvian Oncological Centre / Riga Eastern Clinical University Hospital, Riga, Latvia
🇮🇳
Shatabdi Superspeciality Hospital, Nashik, Maharashtra, India
🇸🇰
Narodny onkologicky ustav, Bratislava, Slovakia

and more 36 locations

Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis

Completed

Conditions: Ankylosing Spondylitis

Interventions: Drug: Etanercept

First Posted Date: 2007-10-16

Last Posted Date: 2015-05-12

Lead Sponsor: Pfizer

Target Recruit Count: 1715

Registration Number: NCT00544557

Locations: 🇩🇪
Klinikum Benjamin Franklin, Berlin, Germany

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

Phase 3

Completed

Conditions: Hemophilia A

Interventions: Biological: Moroctocog alfa (AF-CC)

First Posted Date: 2007-10-15

Last Posted Date: 2019-01-11

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT00543439

Locations: 🇹🇷
Istanbul Universtesi Istanbul Tip Fakultesi, Capa, Istanbul, Turkey
🇷🇴
Sanador, Bucuresti, Romania
🇹🇷
Erciyes Universitesi Tip Fakultesi, Kayseri, Turkey

and more 25 locations

A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder

Phase 3

Completed

Conditions: Generalized Anxiety Disorder

Interventions: Drug: PD 0332334
Drug: Placebo

First Posted Date: 2007-10-11

Last Posted Date: 2012-11-16

Lead Sponsor: Pfizer

Target Recruit Count: 551

Registration Number: NCT00542685

Locations: 🇺🇸
Pfizer Investigational Site, Middleton, Wisconsin, United States

A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction

Phase 2

Completed

Conditions: Dental Pain

Interventions: Drug: Placebo; oral
Drug: ARRY-371797, p38 inhibitor; oral

First Posted Date: 2007-10-10

Last Posted Date: 2021-02-21

Lead Sponsor: Pfizer

Target Recruit Count: 103

Registration Number: NCT00542035

Locations: 🇺🇸
SCIREX Research Center, Salt Lake City, Utah, United States

A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight

Phase 2

Completed

Conditions: Weight Management
Treatment Of Obesity

Interventions: Drug: CE-326,597 100 mg QD
Drug: CE-326,597 50 mg QD
Drug: CE-326,597 25 mg QD
Drug: Placebo
Drug: CE-326,597 5mg QD

First Posted Date: 2007-10-10

Last Posted Date: 2012-11-07

Lead Sponsor: Pfizer

Target Recruit Count: 252

Registration Number: NCT00542009

Locations: 🇪🇸
Pfizer Investigational Site, Sevilla, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy